EU AI Act Medical AI Compliance Costs: A Taiwan ISO 42001 Governance Guide

Winners Consulting Services Co., Ltd. points out that a 2025 study published on arXiv, "Balancing Innovation and Control: The European Union AI Act in an Era of Global Uncertainty," reveals a core conflict that Taiwanese companies cannot ignore: the EU AI Act classifies medical AI as a high-risk artificial intelligence system, with compliance certification costs reaching €16,800 to €23,000 per AI unit and annual compliance fees as high as €29,277. This means that small and medium-sized Taiwanese medical technology enterprises must start building an AI governance framework compliant with the ISO 42001 standard now, or risk missing the market window.

About the Authors and This Study

This paper was co-authored by scholars E. Bignami, Michele Russo, and F. Semeraro, and published on the arXiv preprint platform in 2025. It has accumulated 7 citations, including 2 high-impact ones. Co-author Michele Russo has an h-index of 1 with 63 total citations, focusing on the intersection of AI regulatory policy and health tech governance.

The authors' backgrounds span legal compliance, medical informatics, and geopolitical analysis, giving the paper a rare multidisciplinary perspective. They not only analyze the regulatory text of the European AI Act but also assess the specific impacts of geopolitical factors—such as the US-China semiconductor tariff war and budget displacement from EU rearmament—on the medical AI supply chain. This dual focus on macro and micro factors is the primary reason why this paper is essential reading for Taiwanese corporate executives.

Notably, the research methodology includes a systematic review of the EU AI Act's articles, analysis of multi-stakeholder statements, and several real-world case studies. The authors also convened multidisciplinary experts to propose feasible recommendations, making the study's conclusions highly practical and actionable.

The Tug-of-War Between Innovation and Control: Analyzing the EU AI Act's Double-Edged Sword Effect Through Four Core Findings

The paper's most significant contribution is quantifying compliance costs with precise financial figures and integrating geopolitical risks into the AI governance discussion—a rare approach in existing academic literature. Here is an in-depth analysis of four key findings:

Finding 1: High-Risk Classification Creates Quantifiable Financial Pressure for Compliance

The paper clearly states that the AI Act categorizes all medical AI systems as high-risk, a classification that directly triggers stringent requirements for transparency, data governance, and human oversight. Financially, the certification cost per AI unit ranges from €16,800 to €23,000, with annual ongoing compliance costs around €29,277. For small and medium-sized medical startups with limited resources, this represents a significant barrier to entry. The paper further suggests that these high compliance costs may inadvertently strengthen the market monopoly of "superstar firms," as only large-scale organizations can absorb these expenses, while smaller players risk being marginalized.

Finding 2: Geopolitical Instability Amplifies Supply Chain Vulnerability

The unique contribution of this paper is that it goes beyond analyzing the regulation itself to incorporate geopolitical factors like the US-China semiconductor tariff war and increased EU defense spending into its analytical framework. The paper notes that as EU member states shift more of their budgets toward rearmament, funding for medical AI R&D is crowded out. Simultaneously, US-China chip control measures create high uncertainty in the AI hardware supply chain, directly impacting the availability and accessibility of medical AI systems. This holds significant strategic warning value for Taiwanese companies, as Taiwan is at the heart of the semiconductor supply chain and must carefully assess the potential impact of geopolitics on its own AI product development.

Finding 3: Regulatory Sandboxes and AI Literacy Programs Are Viable Mitigation Strategies

To address the dilemma between innovation and control, the paper proposes three concrete and actionable mitigation measures: first, regulatory sandboxes allow innovative companies to test AI systems in a supervised environment, reducing pre-market entry compliance risks; second, AI literacy programs help healthcare professionals understand the capabilities and limitations of AI systems, improving the quality of human oversight; and third, collaboration and standardization of international compliance frameworks can prevent conflicts between national regulations and reduce redundant cross-border compliance efforts.

Finding 4: Human-Augmented AI is the Core Path to Balancing Safety and Innovation

The paper specifically emphasizes that medical AI systems relying solely on autonomous algorithmic decision-making face the strictest scrutiny under the EU AI Act framework. In contrast, the "human-augmented AI" model—where AI assists rather than replaces human professional judgment—is not only more likely to pass compliance reviews but also better able to strike a balance between regulatory requirements and clinical innovation. This insight offers direct guidance for the product design strategies of Taiwanese medical AI developers.

Strategic Implications for AI Governance in Taiwan: More Than Compliance, It's Key to Market Access

The most direct implication of this paper for Taiwanese companies is that the compliance pressure from the EU AI Act is not a distant European issue, but a decisive factor determining whether Taiwan's medical technology, biotech, and AI software firms can enter the world's largest regulatory market. Taiwan's AI Basic Act has been progressively rolled out since 2024. Although Taiwan's regulatory framework differs from the EU's, the AI management system framework established by ISO 42001 is highly compatible across different frameworks, making it the most effective path for Taiwanese companies to simultaneously meet local regulations and EU AI Act requirements.

Specifically, Taiwanese companies should now focus on the following three aspects:

First, conduct a risk level assessment of AI systems. Following the EU AI Act's classification logic, Taiwanese companies should inventory their developed or deployed AI systems to assess whether they fall into the high-risk category. Functions such as medical diagnostic assistance, patient risk assessment, and medication dosage decisions will almost certainly be classified as high-risk and must be prioritized for compliance planning.

Second, establish a documentation system for an AI management system compliant with ISO 42001. The transparency and data governance obligations highlighted in the paper are core requirements of the ISO 42001 standard. If Taiwanese companies can establish this documentation system in advance, they can not only handle EU AI Act audits but also demonstrate good AI governance practices under Taiwan's AI Basic Act regulatory framework.

Third, incorporate geopolitical risks into AI supply chain assessments. The paper reminds us that uncertainty in the semiconductor supply chain directly affects the sustainable operation of AI systems. Taiwanese companies should clearly identify single points of failure in their supply chain within their AI governance framework and establish backup mechanisms, which is also a practical application of ISO 42001's risk management requirements.

How Winners Consulting Services Helps Taiwanese Companies Tackle EU AI Act Compliance Challenges

Winners Consulting Services Co., Ltd. helps Taiwanese companies establish AI management systems that comply with ISO 42001 and the EU AI Act, conduct AI risk classification assessments, and ensure their artificial intelligence applications align with Taiwan's AI Basic Act. In response to the financial compliance pressures revealed in this paper (certification costs of €16,800-€23,000 per AI unit), Winners Consulting Services offers a systematic consulting approach to help businesses build a sustainable compliance mechanism while controlling costs.

1. AI System Risk Classification Assessment: We assess the compliance obligation level of a company's existing AI applications one by one, based on the EU AI Act's high-risk category definitions. This helps prioritize high-risk systems that require immediate action and provides a precise basis for resource allocation in subsequent certification planning.
2. ISO 42001 Management System Implementation: We assist companies in designing, documenting, and internally auditing an ISO 42001 AI management system within 7 to 12 months. This involves establishing a complete governance framework that includes risk management, transparency requirements, and human oversight mechanisms, while ensuring compatibility with Taiwan's AI Basic Act.
3. Geopolitical Supply Chain Resilience Assessment: Echoing the paper's warning about supply chain vulnerability, we help companies integrate AI system supply chain risks into their ISO 42001 risk management framework. This includes identifying specific risk points like semiconductor dependency and cross-border data flows, and developing a Business Continuity Plan (BCP) to ensure the long-term availability of AI services.

Frequently Asked Questions

The EU AI Act classifies medical AI as high-risk. How high are the compliance costs for Taiwanese med-tech companies?

According to this paper's research findings, under the EU AI Act's high-risk classification, the certification cost for each medical AI unit ranges from €16,800 to €23,000, with annual ongoing compliance maintenance fees reaching €29,277. This means that small and medium-sized Taiwanese med-tech enterprises planning to enter the EU market must incorporate these costs into their product pricing and financing strategies. It is advisable to prioritize establishing an ISO 42001 AI management system to systematically manage compliance documentation, reduce the labor required for each audit, and thereby lower long-term total compliance costs. Our consulting experience at Winners Consulting Services shows that a well-established documentation system significantly reduces ad-hoc expenses during the certification cycle.

What are the most common EU AI Act-related compliance challenges for Taiwanese companies when implementing ISO 42001?

Taiwanese companies typically face three major challenges. First is the ambiguity in determining the risk level of their AI systems, as many are unsure if their products fall into the high-risk category defined in Annex III of the EU AI Act, leading to inaccurate compliance planning. Second is the conflict between transparency requirements and technical reality; the Act demands explainable AI decisions, which is difficult to achieve with "black box" deep learning models, but ISO 42001's transparency management requirements offer a practical solution framework. Third is the dual compliance pressure from Taiwan's AI Basic Act and the EU AI Act, requiring companies to build a single management system that satisfies both frameworks to avoid redundant efforts and resource waste.

How long does ISO 42001 certification take, and what are the specific steps?

Based on our consulting experience at Winners Consulting Services, achieving ISO 42001 certification from scratch in Taiwan typically takes 7 to 12 months. This is divided into four phases: Phase one (1-2 months) involves a current-state diagnosis and gap analysis to identify discrepancies between existing AI governance and the ISO 42001 standard. Phase two (2-4 months) focuses on management system design and documentation, including creating an AI risk assessment framework, transparency policy, and human oversight procedures. Phase three (2-3 months) is for system trial runs and internal audits to verify effectiveness. The final phase (1-2 months) is the certification audit by an external body. Companies already certified with ISO 27001 or ISO 9001 can often shorten this timeline to 5-7 months by leveraging existing governance frameworks.

How can SMEs evaluate the ROI of investing in AI governance?

The return on investment for an ISO 42001 AI governance framework can be assessed from three perspectives. First is market access value: the EU is the world's largest regulatory market, and compliance with the EU AI Act is a prerequisite for entry, making the investment a market access fee rather than a pure cost. Second is risk mitigation benefit: this paper notes that non-compliant AI systems face fines up to €30,000,000 or 6% of global annual turnover (Article 71 of the EU AI Act), making proactive investment in compliance far more cost-effective. Third is internal governance benefit: an ISO 42001 framework reduces post-deployment incidents, lowers costly post-event remediation, and enhances the company's compliance safety margin under Taiwan's AI Basic Act.

Why choose Winners Consulting Services for assistance with AI governance issues?

Winners Consulting Services Co., Ltd. specializes in ISO management system certification consulting and AI governance framework implementation, with extensive cross-industry experience in Taiwan. Our core strengths are threefold. First, we are proficient in both the technical details of ISO 42001 and the legal requirements of the EU AI Act, enabling us to help clients build a single system that satisfies both frameworks and avoids redundant effort. Second, we have a deep understanding of Taiwan's AI Basic Act, ensuring compliance with both international standards and local regulations. Third, our pragmatic gap-analysis approach optimizes existing systems rather than rebuilding from scratch, effectively shortening implementation time and reducing costs. Apply for a free diagnosis now to understand your company's current AI governance posture and improvement path.